2023 World Conference on Lung Cancer (Posters)-EP13.03. A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients

EP13.03. A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients - PDF(Slides)

Back to course

Pdf Summary

A comparative analysis was conducted by Luca Marzano from KTH Royal Institute of Technology to evaluate the differences in outcomes for small-cell lung cancer (SCLC) patients between real-world data (RWD) and clinical trials. The study included a mixed cohort of patients with stage IV SCLC who received platinum-based chemotherapy. The retrospective real-world data was obtained from Karolinska University Hospital and the comparative group included open data from three randomized phase III clinical trials. Cox hazard ratios were calculated for overall survival based on aggregated data, and the analysis included covariates such as age, sex, brain metastasis, ECOG performance status, and the data source.<br /><br />The results showed that the overall survival median for the study cohort was 8 months. Significant hazard ratios were observed for sex and performance status. The real-world data from Karolinska University Hospital provided a worse prognosis compared to the clinical trials. Censoring in the clinical trials had a significant impact on the outcomes, but after removing censored patients, the hazard ratios for the different studies were not statistically significant except for one trial. <br /><br />The study concluded that two of the three clinical trials had similar outcomes compared to the real-world dataset, suggesting the potential utilization of real-world data for making decisions for SCLC patients. The analysis also highlighted the discrepancy in outcomes between real-world data and clinical trials, emphasizing the different operations between these two settings.<br /><br />Luca Marzano's work on this project was recognized with the Conquer Cancer ASCO Foundation Abstract Award at ASCO Breakthrough in Yokohama 2023. The project was conducted in collaboration with the Department of Oncology-Pathology and the Thoracic Oncology Center, and was supported by the Centre for Data-Driven Health at KTH Royal Institute of Technology.

Asset Subtitle

Luca Marzano

Meta Tag

Speaker Luca Marzano

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

comparative analysis

small-cell lung cancer

real-world data

clinical trials

overall survival

hazard ratios

prognosis

censored patients

outcomes

utilization of real-world data